Milestone Payments for Licensed Products. Connetics shall make the following cash milestone payments to Genentech:
Milestone Payments for Licensed Products. In further consideration of the grant of the license by ImmunoGen hereunder, and subject to the other terms of this Agreement, Lilly will make the following payments to ImmunoGen in accordance with Section 5.6(d) hereof within [***] days after Lilly’s receipt of an invoice from ImmunoGen reflecting the first occurrence of each of the milestones set forth below: Clinical Milestones Milestone Payment
Milestone Payments for Licensed Products. Pfizer shall pay Rigel, within sixty (60) days of the completion of each event set forth below ("Event"), the payment listed opposite that Event. Payments shall be made in U.S. dollars by wire transfer in immediately available funds to a U.S. bank account designated by Rigel, or other mutually acceptable means. Pfizer shall be obligated to make each payment only once with respect to each Licensed Product affected by an Event and such payment for such Event shall not be due with respect to any subsequent Licensed Product directed to a Molecular Target and indication which has previously been the subject of the same Event. With the exception of any such milestone paid to Rigel for the occurrence of the earlier of Submission of IND or initiation of human (Section 3.12.1(i)) or animal (Section 3.12.2(i)) clinical trials, payments made by Pfizer pursuant to this Section 3.12 with respect to a Licensed Product shall be credited against sums due to Rigel pursuant to Section 3.8 of this Agreement with respect to Net Sales of such Licensed Product. Fifty percent (50%) of the milestone payment paid to Rigel for commencement of Phase III human clinical trials (Section 3.12.1(ii)) and submission of NADA for animal use (Section 3.12.2 (ii)) shall be credited against royalty payments and one hundred percent (100%) of milestone payments paid to Rigel for NDA/PLA filing for human use (Section 3.12.1 (iii)) and for NADA/PLA approval in any country for animal use (Section 3.12.2 (iii)); PROVIDED, HOWEVER, that the sums due pursuant to Section 3.8 in any calendar year with respect to such Licensed Product shall not be reduced by virtue of this credit by more than fifty percent (50%):
Milestone Payments for Licensed Products. In further consideration of the grant of the license by ImmunoGen hereunder, and subject to the other terms of this Agreement, Novartis will make the following payments to ImmunoGen in accordance with Section 5.6(e) hereof within [***] days after the first occurrence of each of the milestones set forth below and receipt of a corresponding invoice substantially in the form attached hereto as Schedule B: Development and Commercialization Milestones Milestone Payment
Milestone Payments for Licensed Products. Subject to Sections 4.4 through 4.8 below, once a payment has been made under any particular Milestone Event for a Licensed Product, achievement of that same Milestone Event for a different Licensed Product shall not trigger an additional payment obligation. With respect to each milestone achieved under this Agreement, and as set forth below, within thirty (30) days of the receipt of invoice from Genentech for the first occurrence that each such milestone is achieved, Denali shall pay Genentech the following:
Milestone Payments for Licensed Products. 4.2.1 MILESTONES. ABX will make the following nonrefundable, noncreditable payments to IMMUNOGEN within thirty (30) days after the first achievement of each of the milestones set forth below: Milestone Milestone Payment
Milestone Payments for Licensed Products. All milestone payments described in Section 8.2 (Development Milestone Payments) and Section 8.3 (Sales Milestone Payments) will be paid [**].
Milestone Payments for Licensed Products. Within thirty (30) days of Adolor and/or any Sublicensee achieving a milestone event listed below with respect to the first Licensed Product to reach such milestone, Adolor will pay the following specified non-creditable, non-refundable amount by electronic wire transfer in immediately available funds to an account designated by Lilly: Milestone Event Payment [**] For avoidance of doubt, Adolor shall make each milestone payment to Lilly only for the first Licensed Product to reach such milestone and not for any subsequent Licensed Product(s) that achieve the same milestone event. Notwithstanding anything to the contrary herein, in no event shall the aggregate of all payments due under Section 3.1 exceed [**]. For the avoidance of doubt, in the event that worldwide Net Sales are less than [**] in a given Calendar Year, and in the next Calendar Year worldwide Net Sales are greater than [**], then a milestone payment of [**] would be due to Lilly on account of such Net Sales in the next Calendar Year.
Milestone Payments for Licensed Products. Within [**] days after the first achievement of each of the following milestones by the first Licensed Product to achieve such milestone, Curis shall pay to Genentech the corresponding one-time (except as expressly set forth in Section 4.4) milestone payment set forth below.
Milestone Payments for Licensed Products. In further consideration of the grant of the license by ImmunoGen hereunder, and subject to the other terms of this Agreement, Novartis will make the following payments to ImmunoGen in accordance with Section 5.6(e) hereof within [***] days after the first occurrence of each of the milestones set forth below and receipt of a corresponding invoice substantially in the form attached hereto as Schedule B: Development and Commercialization Milestones Milestone Payment [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. [***] [***] [***] [***] [***] [***] Sales Milestones Milestone Payment [***] [***] [***] [***] [***] [***] [***] [***]
